Latest Johnson & Johnson (JNJ) Headlines
Midday Glance: Pharmaceuticals companies
AP - Fri Mar 14, 12:21PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Fri Mar 14, 12:21PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Philadelphia Jury Awards $3 Million in Topamax Birth Defect Trial
PR Newswire - Fri Mar 14, 11:44AM CDT
A Houston-based plaintiffs firm specializing in drug injury law, Matthews & Associates, won a $3 million jury verdict in Philadelphia district court on March 7 for the family of a 5-year-old girl who suffered a severe cleft lip and cleft palate as a result of Topamax.
Early Glance: Pharmaceuticals companies
AP - Fri Mar 14, 9:50AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Early Glance: Medical Devices companies
AP - Fri Mar 14, 9:50AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Microfluidics Market Report 2013-2018: Materials, Pharmaceuticals, Drug Delivery Devices & IVD
M2 - Fri Mar 14, 9:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7zswzc/microfluidics Normal 0 false false false EN-IE X-NONE X-NONE ) has announced the addition of the "Microfluidics Market Report 2013-2018: Materials, Pharmaceuticals, Drug Delivery Devices & IVD" report to their offering. The microfluidics market is segmented based on materials, products, and applications. This report studies market trends for the above mentioned segments in three industries, namely, pharmaceutical, in-vitro diagnostics, and drug delivery devices. The market is expected to grow at a strong CAGR during the study period. This is due to factors such as the rising demand for POC devices, quick return on investments provided by microfluidics devices which helps in cost reductions, and miniaturization of microfluidic chips. However, factors such as difficulty in incorporation of emerging microfluidic technologies into existing workflows and complex and time consuming regulatory standards are hampering the growth of this market. Microfluidics is defined as the science of designing, fabricating, and formulating products and processes that deal with low volumes of fluids in the range of nanoliters or picoliters. The technology evolved from MEMS (Micro Electro Mechanical Systems) devices and can replicate all the functions of its counterparts in various healthcare applications such as, drug delivery, Point-of-Care (POC), and clinical diagnostics. This study covers the materials, industries, and applications revenue markets for the global market. The global revenue generated from various microfluidics products used in three industries, namely, pharmaceutical, in-vitro diagnostics, and drug delivery devices is considered to estimate the market size. Material - Polymer-based Microfluidics - Glass-based Microfluidics - Silicon-based Microfluidics - Other Material-based Microfluidics Industry Pharmaceuticals - -- Microfluidic Chips for Laboratory Analytics - --- Toxicity Screening - --- Proteomics Analysis - --- Gene Sequencing - --- Capillary Electrophoresis - -- Accurate Dispensing Devices - -- Microreactors for Drug Synthesis - -- In-Vitro Diagnostics - --- Clinical Diagnostics - --- Point--- of--- Care Testing - --- Environmental Testing - --- Industrial Testing - --- Agro Food Testing - -- Drug Delivery Devices - --- Inhaler Nozzles - --- Micro Needles - --- Micro Pumps Application - Drug Delivery - Industrial and Environmental - Analytical Devices - Pharmaceutical and Life Sciences Research - Point-of-Care Diagnostics - Clinical and Veterinary Diagnostics Companies Mentioned - Abbott Laboratories, Inc. - Agilent Technologies - Bartels Mikrotechnik Gmbh - Becton, Dickinson And Company 1 Becton Drive - Bio-Rad Laboratories, Inc. - Biofluidix Gmbh - Cepheid, Inc. - Danaher Corporation - Fluidigm Corporation - Johnson & Johnson - Life Technologies Corporation - Microfluidic Chipshop Gmbh - Perkinelmer, Inc. - Raindance Technologies - Roche Diagnostics Limited - Scienion Ag - Siemens Healthcare For more information visit http://www.researchandmarkets.com/research/7z...rofluidics Normal 0 false false false EN-IE X-NONE X-NONE
Stock Market News for March 14, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 9:06AM CDT
Rising political tension between Russia and the West over Crimea dragged the benchmarks down to their worst fall in over five weeks
Better Buy: Johnson & Johnson, Pfizer, or Bristol-Myers Squibb?
Peter Stephens, The Motley Fool - Motley Fool - Fri Mar 14, 8:30AM CDT
Shares in Johnson & Johnson gained a healthy 31.8% in 2013. This outpaced its Dow peer Pfizer , but trailed the stock rise posted by sector competitor Bristol-Myers Squibb . ...
Concise Anlaysis of the Chinese Orthopedic Instrument Industry
M2 - Fri Mar 14, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t7d4nc/china_orthopedic) has announced the addition of the "Concise Anlaysis of the Chinese Orthopedic Instrument Industry" report to their offering. Benefiting from aging of population, consumption upgrade and policy support, China's orthopedic instrument industry has seen rapid development over the years, with total market size rising from 3.28 billion yuan in 2006 to 9.85 billion yuan in 2012. Trauma products, spine products and joint products constitute the three major market segments of Chinese orthopedic instrument industry. In 2012, the three principal products accounted for an aggregate market share of about 82.2%, of which, trauma products showed the highest, approximately 35.5%, with market size up 18.24% YoY; spine and joint products ranked second (up 12.6% YoY) and third (up 12.4% YoY), respectively. In recent years, along with the increasing investment of foreign-funded enterprises in China, the trend of foreign monopoly has been more evident. After the acquisition of Synthes in 2012, Johnson & Johnson has turned into the largest company in China's orthopedic instrument market, with market share of both trauma and spine products occupying the first place. In November 2012, Medtronic purchased KangHui Medical for $816 million, thus making an important step in Chinese orthopedic instrument market localization. Compared with Medtronic's high-end positioning, affordable KangHui products can help Medtronic expand low- and medium-end markets in emerging countries and regions (including China). In 2012, Medtronic (including KangHui Medical) occupied 15.9% of China's spine market. Key Topics Covered: 1. Overview of Orthopedic Instrument Industry 2. Development of Global Orthopedic Instrument Industry 3. Development of China Orthopedic Instrument Industry 4. Development Environment for China Orthopedic Instrument Industry 5. Key Companies in China Companies Mentioned: - Beijing AKEC Medical Co. Ltd. (AKEC) - Beijing Lidakang Science and Technology Co., Ltd. - Beijing Montagne Medical Device Co., Ltd. - Johnson & Johnson - Medtronic - Renli Orthopedics Medical Instrument Limited Company - Shanghai Kinetic Medical Co., Ltd. (KMC) - Stryker - Suzhou Xinrong Best Medical Instrument Co,. Ltd. - Tianjin Walkman Biomaterial Co., Ltd. - United Orthopedic Corporation - Weigao For more information visit http://www.researchandmarkets.com/research/t7...orthopedic
Concise Analysis of the International Endovascular Cerebral Aneurysm Repair Market
M2 - Fri Mar 14, 6:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6s7ggx/endovascular) has announced the addition of the "Concise Analysis of the International Endovascular Cerebral Aneurysm Repair Market" report to their offering. The global market for the endovascular treatment of cerebral aneurysms, which currently stands at US$980 million, is expected to reach $1.4 billion by 2020, a compound average annual growth rate of 5% per year. The market, which has grown significantly since its inception in the mid-90s, has evolved recently through strategic acquisitions, iterative improvement of embolic coils and aneurysm stents as well as the introduction of flow diversion devices. Endovascular Cerebral Aneurysm Repair Market Report is an exclusive update to the recently changed global landscape of this market. It provides a brief, but thorough, analysis of the market with profiles of leading participant's neurovascular intervention divisions and a global forecast to the year 2020. Key Topics Covered: 1. Global Endovascular Cerebral Aneurysm Repair (ECAR) Market 2. Leading Companies & Their Devices 2.1 Stryker: Neurovascular Business Unit 2.2 Covidien: Neurovascular Business Unit 2.3 Johnson & Johnson: Codman Neurovascular Business Unit 2.4 Terumo: MicroVention Neurovascular Business Unit 2.5 Balt Extrusion 3. Leading Companies Market Shares 4. Geographic Segmentation 4.1 US Endovascular Cerebral Aneurysm Repair (ECAR) Market 4.2 European Endovascular Cerebral Aneurysm Repair (ECAR) Market 4.3 Japanese Endovascular Cerebral Aneurysm Repair (ECAR) Market 4.4 Chinese Endovascular Cerebral Aneurysm Repair (ECAR) Market 4.5 Latin American Endovascular Cerebral Aneurysm Repair (ECAR) Market 5. Other Companies In The Space 6. Endovascular Cerebral Aneurysm Repair Technology Update 7. Mergers, Acquisitions and Valuations in the Neurovascular Space 8. Endovascular Cerebral Aneurysm Repair Market Forecast Companies Mentioned: - Balt - Covidien - Johnson & Johnson (Codman Neurovascular) - Merlin MD - NeuroVasx - Penumbra - Phenox GmbH - Sequent Medical - Stryker - Terumo (MicroVention) - Valor Medical For more information visit http://www.researchandmarkets.com/research/6s...dovascular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
3 Health Care Companies Warren Buffett Loves
Todd Campbell, The Motley Fool - Motley Fool - Thu Mar 13, 5:30PM CDT
Warren Buffett believes in buying companies for the long haul, so Berkshire Hathaway's positions are usually concentrated bets on businesses that are easy to understand. While Buffett's team, which includes Ted Weschler, has found more companies...
Final Glance: Pharmaceuticals companies
AP - Thu Mar 13, 5:05PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were down at the close of trading:
Final Glance: Medical Devices companies
AP - Thu Mar 13, 5:05PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were down at the close of trading:
Bed Bath & Beyond asks vendors to cut chemicals
AP - Thu Mar 13, 2:51PM CDT
NEW YORK (AP) — Home decor retailer Bed Bath & Beyond is asking its vendors to voluntarily cut down use of some harmful chemicals in their products.
Can Eli Lilly Continue its Bull Run?
Peter Stephens, The Motley Fool - Motley Fool - Thu Mar 13, 8:30AM CDT
Investors in Eli Lilly had a disappointing 2013, as shares in the company gained just 5% while the S&P 500 rose by almost 32%. A key reason for the stock's underperformance was the generic drugs that ate...
Concise Analysis of the International Orphan Drugs Industry
M2 - Thu Mar 13, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kdwn77/orphan_drugs) has announced the addition of the "Concise Analysis of the International Orphan Drugs Industry " report to their offering. This report analyzes the worldwide markets for Orphan Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Japan, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 113 companies including many key and niche players such as: - AbbVie Inc. - Actelion Pharmaceuticals Ltd. - Amgen Inc. - AstraZeneca plc - Bayer HealthCare AG - Biogen Idec Inc. - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Celgene Corporation - CEL-SCI Corporation - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Johnson & Johnson - Merck & Co. Inc. - Merck Serono International S.A. - Novartis AG - Pfizer Inc. - Recordati S.p.A. - Orphan Europe - Sanofi SA - Genzyme Corporation. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Growth Drivers And Inhibitors 3. Challenges To Orphan Drug Development 4. Current Market Trends 5. Breakthroughs In Orphan Disease Treatment - A Ray Of Hope 6. Regulatory Scenario 7. Product Overview 8. Recent Orphan Designations & Approvals 9. Recent Industry Activity 10. Focus On Select Players 11. Global Market Perspective III. Market 1. The United States 2. Japan 3. Europe 4. Rest Of World IV. Competitive Landscape Total Companies Profiled: 113 (including Divisions/Subsidiaries - 121) - The United States (61) - Canada (4) - Japan (9) - Europe (42) - France (8) - Germany (3) - The United Kingdom (4) - Italy (4) - Rest of Europe (23) - Asia-Pacific (Excluding Japan) (3) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/kd...phan_drugs
Midday Glance: Pharmaceuticals companies
AP - Fri Mar 14, 12:21PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Fri Mar 14, 12:21PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Philadelphia Jury Awards $3 Million in Topamax Birth Defect Trial
PR Newswire - Fri Mar 14, 11:44AM CDT
A Houston-based plaintiffs firm specializing in drug injury law, Matthews & Associates, won a $3 million jury verdict in Philadelphia district court on March 7 for the family of a 5-year-old girl who suffered a severe cleft lip and cleft palate as a result of Topamax.
Early Glance: Pharmaceuticals companies
AP - Fri Mar 14, 9:50AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Early Glance: Medical Devices companies
AP - Fri Mar 14, 9:50AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Microfluidics Market Report 2013-2018: Materials, Pharmaceuticals, Drug Delivery Devices & IVD
M2 - Fri Mar 14, 9:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7zswzc/microfluidics Normal 0 false false false EN-IE X-NONE X-NONE ) has announced the addition of the "Microfluidics Market Report 2013-2018: Materials, Pharmaceuticals, Drug Delivery Devices & IVD" report to their offering. The microfluidics market is segmented based on materials, products, and applications. This report studies market trends for the above mentioned segments in three industries, namely, pharmaceutical, in-vitro diagnostics, and drug delivery devices. The market is expected to grow at a strong CAGR during the study period. This is due to factors such as the rising demand for POC devices, quick return on investments provided by microfluidics devices which helps in cost reductions, and miniaturization of microfluidic chips. However, factors such as difficulty in incorporation of emerging microfluidic technologies into existing workflows and complex and time consuming regulatory standards are hampering the growth of this market. Microfluidics is defined as the science of designing, fabricating, and formulating products and processes that deal with low volumes of fluids in the range of nanoliters or picoliters. The technology evolved from MEMS (Micro Electro Mechanical Systems) devices and can replicate all the functions of its counterparts in various healthcare applications such as, drug delivery, Point-of-Care (POC), and clinical diagnostics. This study covers the materials, industries, and applications revenue markets for the global market. The global revenue generated from various microfluidics products used in three industries, namely, pharmaceutical, in-vitro diagnostics, and drug delivery devices is considered to estimate the market size. Material - Polymer-based Microfluidics - Glass-based Microfluidics - Silicon-based Microfluidics - Other Material-based Microfluidics Industry Pharmaceuticals - -- Microfluidic Chips for Laboratory Analytics - --- Toxicity Screening - --- Proteomics Analysis - --- Gene Sequencing - --- Capillary Electrophoresis - -- Accurate Dispensing Devices - -- Microreactors for Drug Synthesis - -- In-Vitro Diagnostics - --- Clinical Diagnostics - --- Point--- of--- Care Testing - --- Environmental Testing - --- Industrial Testing - --- Agro Food Testing - -- Drug Delivery Devices - --- Inhaler Nozzles - --- Micro Needles - --- Micro Pumps Application - Drug Delivery - Industrial and Environmental - Analytical Devices - Pharmaceutical and Life Sciences Research - Point-of-Care Diagnostics - Clinical and Veterinary Diagnostics Companies Mentioned - Abbott Laboratories, Inc. - Agilent Technologies - Bartels Mikrotechnik Gmbh - Becton, Dickinson And Company 1 Becton Drive - Bio-Rad Laboratories, Inc. - Biofluidix Gmbh - Cepheid, Inc. - Danaher Corporation - Fluidigm Corporation - Johnson & Johnson - Life Technologies Corporation - Microfluidic Chipshop Gmbh - Perkinelmer, Inc. - Raindance Technologies - Roche Diagnostics Limited - Scienion Ag - Siemens Healthcare For more information visit http://www.researchandmarkets.com/research/7z...rofluidics Normal 0 false false false EN-IE X-NONE X-NONE
Stock Market News for March 14, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 9:06AM CDT
Rising political tension between Russia and the West over Crimea dragged the benchmarks down to their worst fall in over five weeks
Better Buy: Johnson & Johnson, Pfizer, or Bristol-Myers Squibb?
Peter Stephens, The Motley Fool - Motley Fool - Fri Mar 14, 8:30AM CDT
Shares in Johnson & Johnson gained a healthy 31.8% in 2013. This outpaced its Dow peer Pfizer , but trailed the stock rise posted by sector competitor Bristol-Myers Squibb . ...
Concise Anlaysis of the Chinese Orthopedic Instrument Industry
M2 - Fri Mar 14, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t7d4nc/china_orthopedic) has announced the addition of the "Concise Anlaysis of the Chinese Orthopedic Instrument Industry" report to their offering. Benefiting from aging of population, consumption upgrade and policy support, China's orthopedic instrument industry has seen rapid development over the years, with total market size rising from 3.28 billion yuan in 2006 to 9.85 billion yuan in 2012. Trauma products, spine products and joint products constitute the three major market segments of Chinese orthopedic instrument industry. In 2012, the three principal products accounted for an aggregate market share of about 82.2%, of which, trauma products showed the highest, approximately 35.5%, with market size up 18.24% YoY; spine and joint products ranked second (up 12.6% YoY) and third (up 12.4% YoY), respectively. In recent years, along with the increasing investment of foreign-funded enterprises in China, the trend of foreign monopoly has been more evident. After the acquisition of Synthes in 2012, Johnson & Johnson has turned into the largest company in China's orthopedic instrument market, with market share of both trauma and spine products occupying the first place. In November 2012, Medtronic purchased KangHui Medical for $816 million, thus making an important step in Chinese orthopedic instrument market localization. Compared with Medtronic's high-end positioning, affordable KangHui products can help Medtronic expand low- and medium-end markets in emerging countries and regions (including China). In 2012, Medtronic (including KangHui Medical) occupied 15.9% of China's spine market. Key Topics Covered: 1. Overview of Orthopedic Instrument Industry 2. Development of Global Orthopedic Instrument Industry 3. Development of China Orthopedic Instrument Industry 4. Development Environment for China Orthopedic Instrument Industry 5. Key Companies in China Companies Mentioned: - Beijing AKEC Medical Co. Ltd. (AKEC) - Beijing Lidakang Science and Technology Co., Ltd. - Beijing Montagne Medical Device Co., Ltd. - Johnson & Johnson - Medtronic - Renli Orthopedics Medical Instrument Limited Company - Shanghai Kinetic Medical Co., Ltd. (KMC) - Stryker - Suzhou Xinrong Best Medical Instrument Co,. Ltd. - Tianjin Walkman Biomaterial Co., Ltd. - United Orthopedic Corporation - Weigao For more information visit http://www.researchandmarkets.com/research/t7...orthopedic
Concise Analysis of the International Endovascular Cerebral Aneurysm Repair Market
M2 - Fri Mar 14, 6:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6s7ggx/endovascular) has announced the addition of the "Concise Analysis of the International Endovascular Cerebral Aneurysm Repair Market" report to their offering. The global market for the endovascular treatment of cerebral aneurysms, which currently stands at US$980 million, is expected to reach $1.4 billion by 2020, a compound average annual growth rate of 5% per year. The market, which has grown significantly since its inception in the mid-90s, has evolved recently through strategic acquisitions, iterative improvement of embolic coils and aneurysm stents as well as the introduction of flow diversion devices. Endovascular Cerebral Aneurysm Repair Market Report is an exclusive update to the recently changed global landscape of this market. It provides a brief, but thorough, analysis of the market with profiles of leading participant's neurovascular intervention divisions and a global forecast to the year 2020. Key Topics Covered: 1. Global Endovascular Cerebral Aneurysm Repair (ECAR) Market 2. Leading Companies & Their Devices 2.1 Stryker: Neurovascular Business Unit 2.2 Covidien: Neurovascular Business Unit 2.3 Johnson & Johnson: Codman Neurovascular Business Unit 2.4 Terumo: MicroVention Neurovascular Business Unit 2.5 Balt Extrusion 3. Leading Companies Market Shares 4. Geographic Segmentation 4.1 US Endovascular Cerebral Aneurysm Repair (ECAR) Market 4.2 European Endovascular Cerebral Aneurysm Repair (ECAR) Market 4.3 Japanese Endovascular Cerebral Aneurysm Repair (ECAR) Market 4.4 Chinese Endovascular Cerebral Aneurysm Repair (ECAR) Market 4.5 Latin American Endovascular Cerebral Aneurysm Repair (ECAR) Market 5. Other Companies In The Space 6. Endovascular Cerebral Aneurysm Repair Technology Update 7. Mergers, Acquisitions and Valuations in the Neurovascular Space 8. Endovascular Cerebral Aneurysm Repair Market Forecast Companies Mentioned: - Balt - Covidien - Johnson & Johnson (Codman Neurovascular) - Merlin MD - NeuroVasx - Penumbra - Phenox GmbH - Sequent Medical - Stryker - Terumo (MicroVention) - Valor Medical For more information visit http://www.researchandmarkets.com/research/6s...dovascular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
3 Health Care Companies Warren Buffett Loves
Todd Campbell, The Motley Fool - Motley Fool - Thu Mar 13, 5:30PM CDT
Warren Buffett believes in buying companies for the long haul, so Berkshire Hathaway's positions are usually concentrated bets on businesses that are easy to understand. While Buffett's team, which includes Ted Weschler, has found more companies...
Final Glance: Pharmaceuticals companies
AP - Thu Mar 13, 5:05PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were down at the close of trading:
Final Glance: Medical Devices companies
AP - Thu Mar 13, 5:05PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were down at the close of trading:
Bed Bath & Beyond asks vendors to cut chemicals
AP - Thu Mar 13, 2:51PM CDT
NEW YORK (AP) — Home decor retailer Bed Bath & Beyond is asking its vendors to voluntarily cut down use of some harmful chemicals in their products.
Can Eli Lilly Continue its Bull Run?
Peter Stephens, The Motley Fool - Motley Fool - Thu Mar 13, 8:30AM CDT
Investors in Eli Lilly had a disappointing 2013, as shares in the company gained just 5% while the S&P 500 rose by almost 32%. A key reason for the stock's underperformance was the generic drugs that ate...
Concise Analysis of the International Orphan Drugs Industry
M2 - Thu Mar 13, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kdwn77/orphan_drugs) has announced the addition of the "Concise Analysis of the International Orphan Drugs Industry " report to their offering. This report analyzes the worldwide markets for Orphan Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Japan, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 113 companies including many key and niche players such as: - AbbVie Inc. - Actelion Pharmaceuticals Ltd. - Amgen Inc. - AstraZeneca plc - Bayer HealthCare AG - Biogen Idec Inc. - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Celgene Corporation - CEL-SCI Corporation - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Johnson & Johnson - Merck & Co. Inc. - Merck Serono International S.A. - Novartis AG - Pfizer Inc. - Recordati S.p.A. - Orphan Europe - Sanofi SA - Genzyme Corporation. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Growth Drivers And Inhibitors 3. Challenges To Orphan Drug Development 4. Current Market Trends 5. Breakthroughs In Orphan Disease Treatment - A Ray Of Hope 6. Regulatory Scenario 7. Product Overview 8. Recent Orphan Designations & Approvals 9. Recent Industry Activity 10. Focus On Select Players 11. Global Market Perspective III. Market 1. The United States 2. Japan 3. Europe 4. Rest Of World IV. Competitive Landscape Total Companies Profiled: 113 (including Divisions/Subsidiaries - 121) - The United States (61) - Canada (4) - Japan (9) - Europe (42) - France (8) - Germany (3) - The United Kingdom (4) - Italy (4) - Rest of Europe (23) - Asia-Pacific (Excluding Japan) (3) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/kd...phan_drugs
